A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

NCT01678755 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

157

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: ABT-126
DRUG: ABT-126
DRUG: Placebo

Sponsor

AbbVie (prior sponsor, Abbott)